Patterson Companies (PDCO)
(Delayed Data from NSDQ)
$20.76 USD
-0.29 (-1.38%)
Updated Nov 12, 2024 04:00 PM ET
After-Market: $20.87 +0.11 (0.53%) 6:26 PM ET
4-Sell of 5 4
A Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$20.76 USD
-0.29 (-1.38%)
Updated Nov 12, 2024 04:00 PM ET
After-Market: $20.87 +0.11 (0.53%) 6:26 PM ET
4-Sell of 5 4
A Value F Growth B Momentum C VGM
Zacks News
Dentsply International (XRAY) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of 4.17% and 0.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 2.61% and 4.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Patterson Companies (PDCO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Patterson Companies (PDCO) stock based on the movements in the options market lately.
Here's Why You Should Retain PDCO Stock in Your Portfolio for Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies on the back of its broad product line.
PDCO Shares Gain Following New Deals to Boost Animal Health Business
by Zacks Equity Research
Patterson Companies announces to invest in two separate businesses to boost its animal health business.
Why Is Patterson Cos. (PDCO) Down 4.2% Since Last Earnings Report?
by Zacks Equity Research
Patterson Cos. (PDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain PDCO Stock in Your Portfolio for Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies on the back of its broad product line.
PDCO Stock Falls on Q1 Earnings & Sales Miss, Gross Margin Up Y/Y
by Zacks Equity Research
Patterson Companies' first-quarter fiscal 2025 results reflect the negative impact of a cyberattack on its vendor, Change Healthcare.
Patterson Cos. (PDCO) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Patterson Cos. (PDCO) give a sense of how its business performed in the quarter ended July 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Patterson Cos. (PDCO) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Patterson Cos. (PDCO) delivered earnings and revenue surprises of -25% and 3.59%, respectively, for the quarter ended July 2024. Do the numbers hold clues to what lies ahead for the stock?
Broad Portfolio to Aid Patterson Companies' (PDCO) Q1 Earnings
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments on the back of comprehensive product offerings.
Stay Ahead of the Game With Patterson Cos. (PDCO) Q1 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Patterson Cos. (PDCO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended July 2024.
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of 14.71% and 40.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
U.S. Physical Therapy (USPH) Lags Q2 Earnings Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of -9.88% and 3.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Hold Patterson Companies (PDCO) in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of -19.05% and 36.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Tops Q1 Earnings Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 10.06% and 4.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Patterson (PDCO) Expands AI Solutions in Canada via Alliance
by Zacks Equity Research
Patterson Companies (PDCO) unit and Pearl collaborate to bring advanced AI disease detection technology, Second Opinion, to Canada's dental practices, enhancing clinical performance and patient communication
Patterson Companies (PDCO) Aims to Streamline Patient Experience
by Zacks Equity Research
Patterson Companies' (PDCO) latest integration features are likely to provide customers with additional options to streamline their experience.
Patterson Companies (PDCO) Q4 Earnings Miss, Sales Rise Y/Y
by Zacks Equity Research
Patterson Companies' (PDCO) fourth-quarter fiscal 2024 results reflect a year-over-year improvement in Dental Consumable sales, offset by lower Dental Equipment sales. Animal health sales improve.
Patterson Cos. (PDCO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Patterson Cos. (PDCO) give insight into how the company performed in the quarter ended April 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Patterson Cos. (PDCO) Misses Q4 Earnings Estimates
by Zacks Equity Research
Patterson Cos. (PDCO) delivered earnings and revenue surprises of -1.20% and 0.02%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Stay Ahead of the Game With Patterson Cos. (PDCO) Q4 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Patterson Cos. (PDCO), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended April 2024.
What's in Store for Patterson Companies (PDCO) in Q4 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments.
Patterson Companies' (PDCO) Launch to Boost Insurance Workflow
by Zacks Equity Research
Patterson Companies' (PDCO) latest offering is likely to offer customers additional options for their electronic insurance processing and patient billing statement workflow.